story of the week
Pegylated Liposomal Doxorubicin vs Capecitabine as Effective First-Line Therapy for MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Phase III Study Evaluating Pegylated Liposomal Doxorubicin Versus Capecitabine as First-Line Therapy for Metastatic Breast Cancer: Results of the PELICAN Study
Breast Cancer Res Treat 2017 Jan 01;161(1)63-72, N Harbeck, S Saupe, E Jäger, M Schmidt, R Kreienberg, L Müller, BJ Otremba, D Waldenmaier, J Dorn, M Warm, M Scholz, M Untch, M de Wit, J Barinoff, HJ Lück, P Harter, D Augustin, P Harnett, MW Beckmann, SE Al-BatranFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.